FRIDAY, SEPTEMBER 30, 2016

Novan Therapeutics announces positive results of nitric oxide studies

Clinical-stage biotech company Novan Therapeutics announced on Thursday that two studies showed its Nitricil platform technology is efficacious against most multi-drug resistant pathogens.

The results of the preclinical studies, which found that the nitric oxide-releasing technology was effective against antibiotic-resistant bacterium responsible for pneumonia and urinary tract infections, were presented at the Military Health System Research Symposium in Fort Lauderdale, Fla.

"Nitricil is bactericidal and not simply bacteriostatic which means that it kills the bugs instead of just inhibiting growth," Nathan Stasko, the president and co-founder of Novan, said. "The mechanism of action is key. Most antibiotics target specific bugs and often elicit drug-specific resistance. We believe our nitric oxide approach surmounts resistance and induces broad nitrosative and oxidative stress which results in efficacy against a diverse array of microorganisms."

The company said that based on the results of the studies and progress in preclinical programs, it plans to initiate clinical development for the treatment of chronic wound infections resulting from drug-resistant bacteria in the first half of next year.

Novan Therapeutics develops technologies that address issues in nitric oxide delivery, particularly the gaseous species of macromolecules. The company produces nitric oxide treatments in a variety of doses.